ライフサイエンスコーパス: vulnerable plaque

1 of necrosis, or thin-cap fibrous atheromas (vulnerable plaques).

2 ormation of other features characteristic of vulnerable plaque.

3 the treatment of coronary atherosclerosis or vulnerable plaque.

4 s a method for high-resolution assessment of vulnerable plaque.

5 e and may hold promise for identification of vulnerable plaque.

6 0.01 for all), but not with the presence of vulnerable plaque.

7 play an important role in the formation of a vulnerable plaque.

8 ructive nonculprit lesion containing complex vulnerable plaque.

9 of vascular remodeling in the prediction of vulnerable plaque.

10 ctivation in the development of noncalcified vulnerable plaque.

11 as a potential noninvasive method to detect vulnerable plaque.

12 ns with activated complement were found in a vulnerable plaque.

13 atheroma, the most common form of high-risk, vulnerable plaque.

14 plaque imaging may enhance identification of vulnerable plaque.

15 inical as well as pathological evaluation of vulnerable plaques.

16 (1) Rupture-prone plaques are not the only vulnerable plaques.

17 nd rapid progression should be considered as vulnerable plaques.

18 ioscopy may be valuable for the detection of vulnerable plaques.

19 onary syndromes often result from rupture of vulnerable plaques.

20 implicated SLC44A3 in the pathophysiology of vulnerable plaques.

21 tion to include non-flow-limiting, high-risk vulnerable plaques.

22 rongly associated with the presence of focal vulnerable plaques.

23 fied pharmacological and focal treatments of vulnerable plaques.

24 e development of non-flow-limiting high-risk vulnerable plaques.

25 ed the potential of CD163 as a biomarker for vulnerable plaques.

26 nary intervention (PCI) of non-flow-limiting vulnerable plaques.

27 rosclerotic plaques and potentially identify vulnerable plaques.

28 hy is a promising tool for the evaluation of vulnerable plaques.

29 CAD-induced deaths are due to the rupture of vulnerable plaques.

30 g techniques increase diagnostic accuracy of vulnerable plaques.

31 tric mapping of plaques and clearly identify vulnerable plaques.

32 e presence of a lipid core, and therefore of vulnerable plaques.

33 est, especially for the early recognition of vulnerable plaques.

34 IgG can activate macrophages and destabilize vulnerable plaques.

35 ger receptors on macrophages, a biomarker of vulnerable plaques.

36 ne that explicitly evaluate the treatment of vulnerable plaques.

37 es, increased inflammation, and more complex vulnerable plaques.

38 ammatory cells should noninvasively identify vulnerable plaques.

39 therosclerosis, acute coronary syndromes and vulnerable plaques.

40 components that might be useful in targeting vulnerable plaques.

41 between FC accumulation and inflammation in vulnerable plaques.

42 target for drug therapy aimed at stabilizing vulnerable plaques.

43 Is this a vulnerable plaque?

44 dden cardiac death, cardiac arrhythmias, and vulnerable plaque?

45 o two groups: 41 resulting from rupture of a vulnerable plaque (a thin fibrous cap overlying a lipid-

46 strate that macrophages, a characteristic of vulnerable plaques, also assist in expansive remodeling,

47 .7+/-5.1 years), including 1267 (29.2%) with vulnerable plaque and 1474 (34.0%) with plaque progressi

48 tion of at least 50% was rare (25 [3%]), but vulnerable plaque and high Leaman score (ie, >5) were mo

49 This discrepancy between the impact of vulnerable plaque and ischaemia on future adverse events

50 sus document, we cover the new definition of vulnerable plaque and its relationship with vulnerable p

51 ng metalloproteinase that is associated with vulnerable plaque and may be a predictor of cardiovascul

52 LMPs favor the neovascularization within the vulnerable plaque and, in the ruptured plaque, they take

53 larly be a valuable imaging tool to identify vulnerable plaques and associated intraplaque inflammati

54 ance imaging techniques may be able to image vulnerable plaques and characterize plaques in terms of

55 If vulnerable plaques and patients can be successfully iden

56 er consideration as methods to stabilize the vulnerable plaques and patients that might be detected,

57 tic resonance for the noninvasive imaging of vulnerable plaques and the characterization of plaques i

58 carry contrast agents for early detection of vulnerable plaques and the initiation of preventative th

59 ay be distinct from those that predispose to vulnerable plaques and thrombus formation.

60 g the ability of such techniques to diagnose vulnerable plaques and to assess the effects of both pha

61 s on the attempted localization of so-called vulnerable plaques and vulnerable, or high-risk patients

62 oronary plaque, noncalcified plaque, CAC >0, vulnerable plaque, and high CAD burden (Leaman score >5)

63 sity related to CAC >0, noncalcified plaque, vulnerable plaque, and Leaman score >5 (all P <= .002).

64 eaturing occlusive coronary atherosclerosis, vulnerable plaque, and premature death and that these ef

65 ion, endothelial dysfunction, development of vulnerable plaque, and ventricular remodeling following

66 real-time the risk posed by plaques, detect vulnerable plaques, and optimize treatment decisions.

67 aques, the prognostic utility of identifying vulnerable plaques, and the future studies needed to exp

68 Identification and stabilization of vulnerable plaques are important new directions in the t

69 ility, contributing to the concept that more vulnerable plaques are more likely to have a greater deg

70 (2) Vulnerable plaques are not the only culprit factors for

71 Diagnostic techniques to identify vulnerable plaques are rapidly evolving.

72 "Vulnerable" plaques are atherosclerotic plaques that hav

73 acute atherothrombotic vascular occlusion ("vulnerable plaques") are abundant inflammatory mediators

74 cus has been placed on the identification of vulnerable plaques as a means of improving the predictio

75 ries, one of the features that characterizes vulnerable plaques at risk of rupture, can be imaged usi

76 The ability of IVUS to detect vulnerable plaques before rupture is currently being eva

77 s and radiologists as one of the features of vulnerable plaques, but other characteristics-eg, plaque

78 Local treatment of vulnerable plaques by percutaneous coronary intervention

79 tively, metalloproteinases could destabilize vulnerable plaques by promoting matrix destruction, angi

80 hanism by which lipid lowering may stabilize vulnerable plaques by reduced expression and activity of

81 odegradable HDL-NP platform for detection of vulnerable plaques by targeting the collapse of mitochon

82 ard to depiction of the criteria that define vulnerable plaques by using existing MR techniques.

83 Vulnerable plaques can be identified in their quiescent

84 ecause some subtypes of carotid plaques (eg, vulnerable plaques) can predict the occurrence of stroke

85 lprit lesions in patients with ACS have more vulnerable plaque characteristics compared with those wi

86 The identification of vulnerable plaque characteristics with MR imaging aids i

87 dverse cardiac events arising from high-risk vulnerable plaques, compared with optimal medical therap

88 eprocedural symptoms in men, and with a more vulnerable plaque composition in both men and women.

89 of atherosclerosis have evolved beyond the 'vulnerable plaque' concept.

90 our transition from focusing on individual "vulnerable plaque," coronary arterial stenosis, and indu

91 y occlusions will lead to future advances in vulnerable plaque detection technology and potentially l

92 Present "vulnerable plaque" detection technology focuses on ident

93 These 'vulnerable plaques' develop as a consequence of systemic

94 hether the prevalence of untreated high-risk vulnerable plaques differs in STEMI and NSTEMI and affec

95 tent diameters suggests that embolization of vulnerable plaque elements may play a pathogenic role.

96 d plaque, coronary artery calcium (CAC), and vulnerable plaque features using multivariable logistic

97 e in the pathogenesis of atherosclerosis and vulnerable plaque formation, and a fundamental function

98 need to identify the factors responsible for vulnerable plaque formation.

99 al to atherosclerotic lesion development and vulnerable plaque formation.

100 duced in the model of shear stress-modulated vulnerable plaque formation.

101 ssessed in a model of shear stress-modulated vulnerable plaque formation.

102 o diagnose the disease early and distinguish vulnerable plaques from harmless ones.

103 ness (smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52.

104 The recognition of the role of the vulnerable plaque has opened new avenues of opportunity

105 According to the 'response to injury' and 'vulnerable plaque' hypotheses, contractile VSMCs recruit

106 low-limiting (fractional flow reserve >0.80) vulnerable plaques identified via intracoronary imaging.

107 s coronary intervention of non-flow-limiting vulnerable plaques improves clinical outcomes compared w

108 e on the application of AI to the imaging of vulnerable plaque in coronary arteries and provide conse

109 ntial to improve the assessment of images of vulnerable plaque in coronary arteries, but requires rob

110 The ability to image a vulnerable plaque in susceptible patients would theoreti

111 Advances in the understanding of the role of vulnerable plaque in the causation of coronary events, c

112 ecular profiling of a number of proteases in vulnerable plaque in vivo.

113 e clinically useful in imaging the unstable, vulnerable plaques in coronary arteries.

114 ous coronary intervention (PCI) for treating vulnerable plaques in diabetic patients remain unclear.

115 sis, and thinner fibrous caps - all signs of vulnerable plaques in humans.

116 echnology may be well suited for identifying vulnerable plaques in patients.

117 olic activity and characteristic features of vulnerable plaques in patients.

118 y with percutaneous coronary intervention of vulnerable plaques in reducing adverse cardiac events ar

119 The mean (SD) number of vulnerable plaques in the coronary arteries of men in th

120 mpowered the clinician to identify suspected vulnerable plaques in vivo and paved the way for the eva

121 ging catheters (to localize and characterize vulnerable plaque) in combination with future genomic an

122 synchronous plaque motion is associated with vulnerable plaque, in this study, synchronisation patter

123 Characteristic histomorphologic features of vulnerable plaques include a high lipid content, increas

124 Proposed definition criteria of vulnerable plaque included active inflammation, a thin c

125 Unfortunately, the search for the so-called vulnerable plaque is hampered by the lack of both natura

126 Because vulnerable plaque is not an established medical diagnosi

127 Rupture of high-risk, vulnerable plaques is responsible for coronary thrombosi

128 The "vulnerable" plaque is smaller in size, richer in lipids,

129 that until the natural history of presumed "vulnerable plaques" is known one can never truly identif

130 leading to myocardial infarction (so-called "vulnerable plaques") is an important area of cardiovascu

131 h atherosclerotic coronary plaques (known as vulnerable plaques), many of which are non-flow-limiting

132 stological examinations of brain thrombi and vulnerable plaque material from patients with advanced c

133 follow-up, although these large atheromatous vulnerable plaques may angiographically seem mild.

134 Such unstable, vulnerable plaques may be associated with outward remode

135 plaques that cause severe luminal stenosis, vulnerable plaques may cause relatively minor stenosis,

136 Obstructive lesions more commonly harbored vulnerable plaque morphology than nonobstructive lesions

137 Vulnerable plaques most commonly have a large plaque bur

138 can never truly identify what constitutes a "vulnerable plaque." Much work needs to be done in this a

139 elastase and macrophages colocalized in such vulnerable plaques (n=7).

140 ology- and imaging-based definitions of the "vulnerable plaque," necessitating an improved approach f

141 C) was associated with the presence of focal vulnerable plaques (P = 0.01).

142 terol to HDL cholesterol and the presence of vulnerable plaques (P<0.001).

143 es, resulting in an experimentally validated vulnerable plaque phenotype.

144 ion in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary les

145 rden index (LCBI), and the presence of focal vulnerable plaques (plaque burden >=70% and maximum LCBI

146 methods can be used in the future to detect vulnerable plaques, potentially to determine patients' p

147 que, coronary artery calcium (CAC) score >0, vulnerable plaque presence, or Leaman score >5.

148 nosis and might find applications to prevent vulnerable plaque progression.

149 Vulnerable plaques prone to rupture were defined as thos

150 lammatory reaction, the result of which is a vulnerable plaque, prone to rupture and thrombosis.

151 across branch ostia, disruption of adjacent vulnerable plaques, radiation therapy, and extensive pla

152 Passivation of vulnerable plaque represents a therapeutic concept that

153 eatures characteristic of the rupture-prone, vulnerable plaques responsible for acute coronary syndro

154 to enable detection and characterization of vulnerable plaque structure and biology in rabbit abdomi

155 was associated with classical features of a vulnerable plaque, such as a larger lipid core, a higher

156 The most accepted features of vulnerable plaques, such as a large lipid core, increase

157 cept of the vulnerable patient, not just the vulnerable plaque, takes into account the diversity and

158 Vulnerable plaques that had not ruptured were counted in

159 Early identification and treatment of the vulnerable plaque, that is, a coronary artery lesion wit

160 the biological and compositional features of vulnerable plaques, the non-invasive and invasive diagno

161 vasive diagnostic modalities to characterize vulnerable plaques, the prognostic utility of identifyin

162 potential effect of the focal treatment for vulnerable plaques, these findings support consideration

163 wall could digest and weaken fibrous caps of vulnerable plaques, thus provoking thrombosis.

164 possibility of local or regional therapy of "vulnerable plaques" to prevent future events.

165 on Stenosis with Functionally Insignificant Vulnerable Plaque) trial was a randomized clinical trial

166 thrombosis-giving rise to the concept of the vulnerable plaque (VP).

167 udy, the per-patient prevalence of high-risk vulnerable plaques was comparable in STEMI versus NSTEMI

168 inical, as well as pathologic, evaluation of vulnerable plaques was recently put forward in which fiv

169 cope of recent literature on the concept of "vulnerable plaque" was reviewed by examining 463 abstrac

170 including noncalcified, nonobstructive, and vulnerable plaque, was highly prevalent.

171 to develop an imaging agent for detection of vulnerable plaques, we evaluated the feasibility of a li

172 In cases of coronary death, vulnerable plaques were associated with elevated cholest

173 five major and five minor criteria to define vulnerable plaques were proposed.

174 ther proteases, may serve as a biomarker for vulnerable plaques when probed with beacons.

175 with or without and thin-cap fibroatheroma (vulnerable plaque), whereas in erosions and total occlus

176 lesterol - predispose patients to rupture of vulnerable plaques, whereas cigarette smoking predispose

177 As such, it is these vulnerable plaques which are more prone to rapid plaque

178 dvance particularly in the identification of vulnerable plaques, which are associated with specific p

179 The diagnosis of vulnerable plaques, which have the propensity to develop

180 defines histomorphologic characteristics of vulnerable plaques, which may help develop imaging strat

181 o determine whether identifying and treating vulnerable plaques will lead to improved clinical outcom

182 he rate of plaque progression might identify vulnerable plaques with an increased potential for adver

183 ic antibodies allow for in vivo detection of vulnerable plaques with magnetic resonance imaging (MRI)

184 artery plaque but, given to older women with vulnerable plaque, would have a null or even harmful eff